CoChat

Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

Brixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., Fabunmi, R. · 2009 · Diabetes, Obesity and Metabolism
Cited by 38

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim : This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real‐world setting. Methods : Eligible patients identified in the General Electric (GE) electronic medical record (EMR) research database from 1 January 2000 through 31 December 2007 were ≥18 years old with type 2 diabetes. Patients had prescription orders in the previous 395 days for metformin, a sulfonylurea, or a thiazolidinedione as monotherapy or in combination, and had at least 6 months of follow‐up activity. Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow‐up measures documented at 6 months ± 45 days. Results : A total of 1709 patients were identified for study inclusion. The overall mean A1C reduction (s.e.m.) at 6 months was −0.8% (0.05) (p<0.001), weight loss was −3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was −1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and −0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078). Changes in low‐density lipoprotein (LDL), triglycerides and HDL were −7.4 mg/dl (1.7) (p<0.001), −23.2 mg/dl (6.7) (p = 0.001) and −0.8 mg/dl (0.33) (p = 0.012) respectively. In a quartile analysis by weight loss, mean A1C reduction ranged from −1.1 to −0.65% in the highest to lowest weight loss quartiles respectively. Conclusions : In a real‐world setting, exenatide initiation is associated with significant improvements in the measures of clinical effectiveness for type 2 diabetes. These reductions were comparable to those reported in randomized, controlled registration trials after 6 months of therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01081.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 38

Metadata

Authors
Brixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., & Fabunmi, R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2009-11-10
Volume
11
Issue
12
Pages
1122-1130
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2150423648
Cited by
38
References
12
FWCI
3.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01081.x
The paper
Brixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., & Fabunmi, R. (2009). Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01081.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.